Food-Medicine Ingredients Surge as Probiotics Plateau

Executive Summary

China's GI health ingredient landscape is splitting into two speeds: probiotics dominate at CN¥ 26.03 billion but growth has slowed to +3.8% YoY, while food-medicine homology ingredients rooted in traditional Chinese medicine are posting triple-digit gains. Chinese yam surged +666.9% YoY, astragalus climbed +350.6%, and digestive enzymes grew +366.4%, signaling a market inflection point. This analysis examines how ingredient dynamics and delivery format innovation are reshaping competitive positioning for GI health brands.

A Two-Speed Ingredient Landscape

The GI health ingredient market reveals a clear two-speed dynamic. Probiotics remain the dominant force at CN¥ 2.60 billion, representing approximately 67% of the total ingredient market. However, their +3.8% YoY growth signals approaching maturation after years of aggressive category expansion. The real growth momentum has shifted to traditional Chinese medicine-inspired ingredients and functional compounds that are transforming how consumers approach digestive wellness.

Chinese yam leads with extraordinary +666.9% YoY growth to CN¥ 88.1 million, followed by digestive enzymes at +366.4% to CN¥ 76.2 million, and astragalus at +350.6% to CN¥ 97.0 million. These ingredients share several characteristics:

• They align with the food-medicine homology (药食同源) philosophy that has deep cultural resonance in China
• They frequently appear as compound formulations rather than standalone products
• Many are being reformulated into snack-type products to align with contemporary consumption preferences

This convergence of traditional ingredients with modern probiotic science represents a distinctively Chinese innovation pathway that differentiates the domestic market from Western supplement approaches.

Chinese yam (+666.9%) and digestive enzymes (+366.4%) surge while probiotics plateau at +3.8%

Declining Prebiotics Signal a Shift Toward Compound Formulations

Among the declining categories, dietary fiber fell -28.6% to CN¥ 245.8 million, fructo-oligosaccharides declined -16.8% to CN¥ 71.5 million, and inulin dropped -11.7% to CN¥ 76.6 million. These prebiotic ingredients may be losing share as consumers shift toward more comprehensive probiotic-plus-traditional-ingredient compound products that offer perceived holistic benefits rather than single-function prebiotic supplementation.

The emerging ingredients also represent distinct clinical and commercial opportunities:

• Glutamine (+23.6%) is gaining traction through clinical gut repair demand and sports nutrition crossover
• Postbiotics (+28.2%) offer stability advantages over live probiotics for storage and distribution
• Zinc-L-Carnosine (+40.5%), though still at an early CN¥ 1.6 million in sales, precisely targets the H. pylori management and gastric mucosal repair niche with strong clinical evidence support

These specialized ingredients represent the vanguard of the market's evolution toward precision GI health management, moving beyond broad-spectrum probiotics toward condition-specific formulations.

Format Innovation: Drops and Chewables Challenge Powder Dominance

The delivery format landscape reveals a parallel transformation. Powder/sachets remain the primary format at 75.9% share in 2025 (down from 77.7% in 2024), while capsules grew from 10.3% to 11.2%. These two established formats together account for 87% of the market, providing the foundation upon which emerging formats are building.

Powder dominates at 76% share but drops (+78% YoY) and chewables (+48%) emerge

Format YoY Growth Rates

Gummies represent the only declining format at -14% YoY, suggesting that novelty-driven adoption has given way to consumer skepticism about probiotic viability in gummy formulations. This stands in contrast to the broader global trend of gummy supplement growth, indicating that Chinese consumers may apply higher efficacy standards to probiotic delivery formats.

Consumer research reinforces this efficacy-first hierarchy. When purchasing probiotics, efficacy is the dominant consideration at 79%, followed by adverse reactions at 17% and taste at 16%. The narrow gap between adverse reactions and taste indicates that once basic efficacy expectations are met, sensory experience becomes the key differentiator for consumer loyalty and repeat purchases. Format innovation must therefore demonstrate functional credibility before pursuing sensory appeal.

Strategic Implications for Brand Positioning

The convergence of ingredient innovation and format diversification creates a clear strategic framework for GI health brands. Brands that can position products at the intersection of traditional Chinese medicine heritage and modern probiotic science, delivered in convenient new formats, will capture the next wave of growth.

The food-medicine homology ingredients represent a compound formulation opportunity that is distinctly Chinese. Products combining probiotics with astragalus, Chinese yam, and hawthorn align with the traditional "digest, strengthen, nourish" philosophy while meeting modern consumers' demand for scientifically validated functional benefits.

For format strategy, the data suggests investing in drops for the infant segment, chewable tablets for the children and young adult market, and convenient sachets or capsules for the growing portable consumption occasion. Products that fail to deliver a pleasant sensory experience will face competitive disadvantage in reaching the mass market, regardless of formulation quality.

Key Takeaways

• Probiotics dominate at CN¥ 26.03 billion but growth has slowed to +3.8% YoY, signaling category maturation
• Chinese yam (+666.9%), digestive enzymes (+366.4%), and astragalus (+350.6%) lead food-medicine homology ingredient growth
• Prebiotic ingredients are declining as consumers shift toward compound formulations with perceived holistic benefits
• Drops (+78% YoY), chewable tablets (+48%), and oral liquids (+45%) are the fastest-growing delivery formats
• Gummies declined -14% YoY, suggesting Chinese consumers apply higher efficacy standards to probiotic formats

About the Data

This analysis draws on Moojing Market Intelligence data covering January 2024 through September 2025. Moojing tracks 400,000+ brands across 30+ e-commerce platforms, representing 58-65% of China's online retail GMV. For full methodology and additional insights, see the complete GI Health Dietary Supplements & Probiotics whitepaper.